{
    "nct_id": "NCT04238819",
    "official_title": "A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)",
    "inclusion_criteria": "* Parts A and B only:\n\n  * Participants must be less than or equal to (≤)18 years of age.\n  * Body weight greater than or equal to (≥)10 kilograms and body surface area (BSA) ≥0.5\n  * Participants with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies.\n  * For sites that are actively enrolling Parts B and C, participants with neuroblastoma who are eligible for Part C will be excluded from Part B unless approved by Lilly CRP/CRS.\n* Part C only:\n\n  * Participants must be less than (<) 21 years of age.\n  * Participants have a BSA ≥0.2 m².\n  * Participants with first relapse/refractory neuroblastoma.\n* All Parts\n\n  * Participants must have measurable or evaluable disease by RECIST v1.1 or RANO.\n  * A Lansky score ≥50 for participants <16 years of age or Karnofsky score ≥50 for participants ≥16 years of age.\n  * Participants must have discontinued all previous treatments for cancer or investigational agents and must have recovered from the acute effects to Grade ≤1 at the time of enrollment.\n  * Able to swallow and/or have a gastric/nasogastric tube.\n  * Adequate hematologic and organ function ≤2 weeks (14 days) prior to first dose of study drug.\n  * Females of reproductive potential must have negative urine or serum pregnancy test at baseline (within 7 days prior to starting treatment).\n  * Female participants of reproductive potential must agree to use highly effective contraceptive precautions during the trial. For abemaciclib, females should use contraception for at least 3 weeks following the last abemaciclib. For other study drugs, highly effective contraceptive precautions (and avoiding sperm donation) must be used according to their label.\n  * Life expectancy of at least 8 weeks and able to complete at least 1 cycle of treatment.\n  * Caregivers and participants willing to make themselves available for the duration of the trial.\nHealthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Received allogenic bone marrow or solid organ transplant.\n* Received live vaccination.\n* Intolerability or hypersensitivity to any of the study treatments or its components.\n* Diagnosed and/or treated additional malignancy within 3 years prior to enrollment that may affect the interpretation of results, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected in situ cervical and/or breast cancers.\n* Pregnant or breastfeeding.\n* Active systemic infections.\n* Serious and/or uncontrolled preexisting medical condition(s) that would preclude participation in this study.\n* Parts A and C only: Have a bowel obstruction.\n* Prior treatment with drugs known to be strong inhibitors or inducers of isoenzyme cytochrome P450 3A (CYP3A) or strong inhibitors of uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) if the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.\n* Received prior treatment with cyclin-dependent kinase (CDK) 4 & 6 inhibitor.\n* Part C only: Received prior systemic therapy for relapsed/refractory neuroblastoma.\n* Part C only, have received prior anti-GD2 therapy during induction phase.\n* Currently enrolled in any other clinical study involving an investigational product or non-approved use of a drug or device.\n* Has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.",
    "miscellaneous_criteria": ""
}